Tseng CS, Yang JH, Huang SW, Wang YJ, et al. Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer. BMC Cancer 2023;23:568.
PMID: 37340337